On Tuesday Sun Pharma said, its subsidiary has received authorization for emergency use from the Drugs Controller General of India to manufacture and market a generic version of MSD and Ridgeback’s antiviral drug molnupiravir under the brand name Molxvir in India. The recommended dose of the drug is 800 mg twice a day for five days.
The duration of treatment of molnupiravir is much shorter compared to other therapies which is a significant advantage.
Molnupiravir has been developed by MSD and Ridgeback Biotherapeutics.
It has been approved by the US Food and Drug Administration and the UK Medicines and Healthcare products Regulatory Agency for Emergency Use Authorization.
